Yellow fever: a latent danger
DOI:
https://doi.org/10.51481/amc.v47i3.191Keywords:
Arbovirus, yellow fever, zoonosis, haemorragic feverAbstract
Yellow fever is an acute febrile zoonosis, catalogued asa hemorrhagic fever that is potentially deadly. It is causedby an arbovirus and transmitted by an arthropod; there aretwo known epidemiologic modalities, and it has an endem-ic area that comprises most of South America and part of theAfrican continent. In Costa Rica the last outbreak of yellowfever was in the fifties.
The physiopathology of yellow fever is not wellknown. Most of the infections are symptomatic and have ahigh mortality that varies from outbreak to outbreak. The diagnosis is definitely confirmed by serology and althoughthis test isn't performed in Costa Rica, the suspicious sam-ples are sent to Panamanian labs.
Taking into consideration its high mortality and the lackof specific treatment, it's obvious that the only way to dealwith yellow fever is to get rid of the vector and preventionwith massive vaccination in endemic areas.
Yellow fever continues to be an entity that considerablyaffects public health in several countries; Costa Rica hasquite a few conditions that will ease its appearance and dis-semination, that's why this is a disease which's characteris-tics are convenient to keep handy.
Downloads
References
Renan A. La fiebre amarilla en Yucatán durante las épocas precolom-bina y colonial. Biomédica 2000; 11: 301-307.
Mc Carthy, M. A century of the US army yellow fever research.Lancet 2001; 357: 1772.
Strano A, Dooley J, Isaac K. Manual sobre la fiebre amarilla y sudiagnostico diferencial histopatológico. Publicación científica de laOPS No. 299, 1975.
Trejos A, Romero A. Clínica de la fiebre amarilla en Costa Rica. RevBiol Trop 1954; 113-168.
Monath T. Yellow fever: an update. Lancet Infect Dis 2001; 1: 11-20.
Mutebi J, Wang H, Li L, Bryant J., and Barrett A. Phylogenetic andevolutionary relationships among yellow fever virus isolates inAfrica. J Virol 2001; 6999-7008.
Gubler D. Aedes albopticus in Africa. Lancet Infect Dis 2003; l3:751.
Van der Stuyft P, Gianella A, Pirard M, Cespedes J, Lora J, Peredo C,et al. Urbanization of yellow fever in Santa Cruz, Bolivia. Lancet1999; 353: 1558-1562.
Monath T. Facing up to re-emergence of urban yellow fever. Lancet1999; 353: 1541.
OPS. Guías para la vigilancia, prevención y control de la fiebre amar-illa. Publicación Científica no. 410 Organización Panamericana de laSalud 1981.
Velandia M. Fiebre Amarilla Selvática, Colombia 2003. Publicacióndel Instituto Nacional de Salud 2003.
Reiter P, Cordellier R, Ouma J, Cropp B, Savage H, Sanders E, et al.First recorded outbreak of yellow fever in Kenya 1992-1993. Am. JTrop Med Hyg, 1998; 59: 650-656.
Thonnon J, Fontenille D, Tall A, Diallo M, Renaudinean Y, BaudezB, et al. Re-emergence of yellow fever in Senegal in 1995. Am. JTrop Med Hyg 1998; 59: 108-114.
Monath T, Brinker K, Chandler F, Kemp G, Cropp B.Pathophysiologic correlations in a rhesus monkey model of yellowfever. Am J Trop Med Hyg 1981; 30: 431- 41.
Monath T. Yellow fever: a medically neglected disease. Report on aseminar. Rev Infect Dis 1987; 9: 165-175.
Fauci A, Braunwald E, Isselbacher K, Wilson J. Harrison, Principiosde Medicina Interna. Estados Unidos: Editorial Mc Graw-HillInternacional, 1998.124Cuadro 4. Situación del Continente AmericanoPaísesPaíses Requiere vacunaciónendémicospara turistas provenientes de países endémicos BelicexBoliviaxxBrasilxxColombiaxxCosta RicaEcuadorxxEl SalvadorxGuatemalaxGuyana FrancesaxxHondurasxNicaraguaxPanamáxxParaguayxPerúxxVenezuelaxModificado de: www.who.int/ith/Chapter05_10.html.
WHO. Epidemiological bulletin, March 1999; 1: 20.
Vasconcelos P. Diagnosis of viral disease. Lancet 2003; 361: 1589.
Campbell G, Marfin A, Lanciotti R, and Gubler D. West Nile virus.Lancet Infect Dis 2002; 2: 519-529.
Monath T, Ballinger M, Miller B, Salaun J. Detection of yellow feverviral RNA by nucleic acid hybridization and viral antigen byimmunocytochemistry in fixed human liver tissues. Am J Trop MedHyg 1989; 40: 663-68.
Gubler, D. Dengue and dengue hemorrhagic fever. Clin MicrobiolRev 1998; 11: 480-496. 22. Guzmán M, Kourí G. Dengue: an update. Lancet Infect Dis 2002; 2:33-42.
Tierney L, McPhee S, Papadakis M. Current Medical Diagnosis &Treatment 2002. United States, Lange Medical Books/ McGraw-Hill2002.
Berhman R, Kliegman R, Jenson H. Nelson, Tratado de Pediatría.México, Estados Unidos: Editorial McGraw-Hill Interamericana,2001.
Mortimer P. Yellow fever vaccine. BMJ 2002; 324-23; 439.
Monath T, Nichols R, Archambault W, Moore L, Marchesani R, TianJ, et al. Comparative safety and immunogenicity of two yellow fever17d vaccines (arilvax and yf-vax) in a phase III multicenter, double-blind clinical trial. Am. J Trop Med Hyg 2002; 66: 533-541.
Lang J, Zuckerman J, Clarke P, Barrett P, Kirkpatrick C, andBlondeau C. Comparison of the immunogenicity and safety of two17d yellow fever vaccines. Am. J Trop Med Hyg 1999; 60:1045-1050.
Peter G, Hall C, Halsey N, Marcy S, Pickering L. Red Book,Enfermedades Infecciosas en Pediatría. Argentina: Editorial MedicaPanamericana, 1999.
CDC. Yellow Fever Vaccine: Recommendations of the AdvisoryCommittee on Immunizations Practices. MMWR 2002, vol 51 (RR-17).
Sibailly T, Wiktor S, Tsai T, Cropp B, Ekpini E, Adjorlolo-Johnson G,et al. Poor antibody response to yellow fever vaccination in childreninfected with human immunodeficiency virus type 1. Pediatr InfectDis J 1997; 16: 1177
Robert E, Vial T, Schaefer C, Arnon J, Reuvers M. Exposure to yel-low fever vaccine in early pregnancy. Vaccine 1999; 17: 283-85.
Tsai T, Raul R, Lynberg M, Letson G. Congenital yellow fever virusinfection after immunization in pregnancy. J Infect Dis. 1993; 168:1520.
Martin M, Tsai T, Cropp B, Chang G, Holmes D, Tseng J, et al. Feverand multisystem organ failure associated with 17d-204 yellow fevervaccination: a report of four cases. Lancet 2001; 358: 98-104.
Chan R, Penney D, Little D, Carter I, Roberts J, Rawlinson W.Hepatitis and death following vaccination with 17d-204 yellow fevervaccine. Lancet 2001; 358: 121-122.
Vasconcelos P, Luna E, Galler R, Silva L, Coimbra T, Barros V, et al.Serious adverse events associated with yellow fever 17dd vaccineBrazil: a report of two cases. Lancet 2001; 358: 91-97.
Jennings A, Gibson C, Miller B, Mathews J, Mitchell C, Roehrig J, etal, . Analysis of a yellow fever virus isolated from a fatal case of vac-cine-associated human encephalitis. J Infect Dis 1994; 169: 512-18.
WHO, International Travel and Heath. Switzerland: WHO 2005.
WHO, International Heath Regulations (1969): third annotated edi-tion, Geneva, World Health Organization, 1983.
PAHO, Conclusions and recommendations of the technical advisorygroup on vaccine preventable diseases, Municipalities: ImprovingImmunization Services, of the Pan American Health Organization2002. United States: PAHO 2002
Downloads
Published
Issue
Section
License
Copyright (c) 2008 Acta Médica Costarricense
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Los autores que publican en la revista Acta Médica Costarricense pueden distribuir, copiar, remezclar, retocar, leer, descargar, imprimir, buscar y crear a partir de su obra de modo no comercial, indicando los créditos a la revista y sus autores y compartir su obra en las mismas condiciones. Para ello se aplica la licencia Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional(CC BY-NC-SA 4.0)
